MX376822B - Composicion de liberacion demorada que comprende biguanida. - Google Patents

Composicion de liberacion demorada que comprende biguanida.

Info

Publication number
MX376822B
MX376822B MX2015008625A MX2015008625A MX376822B MX 376822 B MX376822 B MX 376822B MX 2015008625 A MX2015008625 A MX 2015008625A MX 2015008625 A MX2015008625 A MX 2015008625A MX 376822 B MX376822 B MX 376822B
Authority
MX
Mexico
Prior art keywords
delayed
composition including
release composition
including biguanide
biguanide
Prior art date
Application number
MX2015008625A
Other languages
English (en)
Spanish (es)
Other versions
MX2015008625A (es
Inventor
Alain D Baron
Mark S Fineman
Stephen Kwaku Dordunoo
Terri Kim
Original Assignee
Anji Pharma Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX376822(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anji Pharma Us Llc filed Critical Anji Pharma Us Llc
Publication of MX2015008625A publication Critical patent/MX2015008625A/es
Publication of MX376822B publication Critical patent/MX376822B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015008625A 2013-01-05 2014-01-03 Composicion de liberacion demorada que comprende biguanida. MX376822B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361749307P 2013-01-05 2013-01-05
PCT/US2014/010240 WO2014107617A1 (en) 2013-01-05 2014-01-03 Delayed-release composition comprising biguanide

Publications (2)

Publication Number Publication Date
MX2015008625A MX2015008625A (es) 2015-09-23
MX376822B true MX376822B (es) 2025-03-07

Family

ID=50030486

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008625A MX376822B (es) 2013-01-05 2014-01-03 Composicion de liberacion demorada que comprende biguanida.
MX2020011594A MX389344B (es) 2013-01-05 2014-01-03 Composición de liberación demorada que comprende biguanida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011594A MX389344B (es) 2013-01-05 2014-01-03 Composición de liberación demorada que comprende biguanida.

Country Status (19)

Country Link
US (3) US20140193498A1 (OSRAM)
EP (2) EP4410380A3 (OSRAM)
JP (1) JP6333855B2 (OSRAM)
KR (1) KR102229492B1 (OSRAM)
CN (2) CN110051638B (OSRAM)
AR (1) AR094374A1 (OSRAM)
AU (1) AU2014203942B2 (OSRAM)
CA (1) CA2896864C (OSRAM)
CL (1) CL2015001914A1 (OSRAM)
CU (1) CU20150071A7 (OSRAM)
EA (1) EA039530B1 (OSRAM)
HK (1) HK1214966A1 (OSRAM)
IL (1) IL239722B (OSRAM)
MX (2) MX376822B (OSRAM)
NZ (1) NZ709525A (OSRAM)
PH (1) PH12015501520A1 (OSRAM)
SG (2) SG10201705437SA (OSRAM)
WO (1) WO2014107617A1 (OSRAM)
ZA (1) ZA201504858B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
CN110693868A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
RS64139B1 (sr) * 2014-12-24 2023-05-31 Principia Biopharma Inc Kompozicije za ileo-jejunalnu isporuku leka
WO2016205754A1 (en) * 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
MX2021014922A (es) * 2019-06-03 2022-03-11 Scherer Technologies Llc R P Capsulas de gel blando de liberacion retardada.
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230000820A1 (en) * 2021-06-28 2023-01-05 ImmunoMet Therapeutics, Inc. Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof
CN119499203A (zh) 2023-08-22 2025-02-25 雅研(天津)生物医药科技中心(有限合伙) 一种盐酸二甲双胍肠溶片
CN119499228A (zh) 2023-08-22 2025-02-25 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1209253A (en) 1913-01-09 1916-12-19 Automatic Electric Co Impulse-transmitting device.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
YU52199A (sh) 1997-04-15 2003-02-28 Csir Corporate Building Farmaceutske kompozicije za suzbijanje apetita
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US7964216B2 (en) * 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
WO2002078617A2 (en) 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
WO2004012715A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
CN1726224A (zh) 2002-12-18 2006-01-25 吉万奥丹股份有限公司 嵌合αQ－Gustducin G－蛋白
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
EP1737442B1 (en) 2004-04-20 2015-01-07 Deutsches Institut Für Ernährungsforschung - Stiftung Des Öffentlichen Rechts - Vertreten Durch Den Stiftungsvorstand Agonists of a bitter taste receptor and uses thereof
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
WO2006053771A2 (en) 2004-11-18 2006-05-26 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Stiftung Des Öffentlichen Rechts Agonists of bitter taste receptors and uses thereof
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
EP1878734A4 (en) 2005-04-28 2010-02-17 Ajinomoto Kk NEW COMPOUND LACTAME
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
CA2612561A1 (en) 2005-06-22 2007-01-04 Senomyx, Inc. Identification of human t2r recepors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators
NZ566642A (en) * 2005-08-30 2011-11-25 Piramal Life Sciences Ltd Extended release pharmaceutical composition of metformin and a process for producing it
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (zh) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 一种促进肠胃蠕动的药物组合物
MX2009001571A (es) 2006-08-17 2009-02-19 Unilever Nv Proceso para la produccion de la planta de hoodia que contiene glucosidos esteroides.
WO2008022875A1 (en) 2006-08-24 2008-02-28 Unilever N.V. Process for preparing a composition comprising steroidal glycosides
CN101522702A (zh) 2006-09-05 2009-09-02 塞诺米克斯公司 人T2R受体hT2R50的新单体型及其在鉴定人苦味调节剂的测定法中的用途
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009053980A2 (en) 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. An improved appetite suppressant
EP2236149B1 (en) 2008-01-29 2014-06-18 Nakamori Pharmaceutical Co., Ltd. Medicinal composition for treating respiratory infectious diseases
EP2306851B1 (en) 2008-05-23 2012-08-01 Givaudan SA Bitter alkaloid containing consumables comprising bitter blockers
WO2009149577A1 (en) 2008-06-13 2009-12-17 Givaudan Sa Methods of identifying modulators of the bitter taste receptor tas2r44
WO2010024393A1 (ja) 2008-08-29 2010-03-04 サントリーホールディングス株式会社 新規エピガロカテキンガレート４量体、およびそれらを含む血管内皮機能改善剤
US8557530B2 (en) 2008-08-29 2013-10-15 Givaudan Sa Use of a TAS2R7 nucleic acid sequence to identify modulators
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
CA2748729A1 (en) 2009-01-03 2010-07-08 Shizuoka Prefecture Public University Corporation Sulfated c-glycoside, method for isolating same and method for synthesizing same
EP2460010A1 (en) 2009-07-28 2012-06-06 Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof
EP2490695B1 (en) 2009-10-21 2013-11-20 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
CA2779906A1 (en) 2009-12-04 2011-06-09 Colgate-Palmolive Company Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
PT2661266T (pt) * 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
CN104349773A (zh) * 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂

Also Published As

Publication number Publication date
US20250000804A1 (en) 2025-01-02
MX389344B (es) 2025-03-20
AU2014203942B2 (en) 2019-01-03
CN105101956A (zh) 2015-11-25
EA201591085A1 (ru) 2015-12-30
JP6333855B2 (ja) 2018-05-30
CN110051638A (zh) 2019-07-26
MX2015008625A (es) 2015-09-23
SG10201705437SA (en) 2017-07-28
KR102229492B1 (ko) 2021-03-17
KR20150103079A (ko) 2015-09-09
CA2896864C (en) 2021-04-20
MX2020011594A (es) 2022-01-13
NZ709525A (en) 2020-07-31
JP2016504384A (ja) 2016-02-12
EP2941245B1 (en) 2024-06-26
ZA201504858B (en) 2018-12-19
EP4410380A2 (en) 2024-08-07
WO2014107617A1 (en) 2014-07-10
CN105101956B (zh) 2018-12-07
CU20150071A7 (es) 2016-01-29
PH12015501520A1 (en) 2015-09-21
IL239722B (en) 2022-04-01
CA2896864A1 (en) 2014-07-10
AU2014203942A1 (en) 2015-07-16
BR112015016111A2 (pt) 2020-01-28
US20140193498A1 (en) 2014-07-10
US20200093750A1 (en) 2020-03-26
AR094374A1 (es) 2015-07-29
EP2941245A1 (en) 2015-11-11
HK1214966A1 (zh) 2016-08-12
CN110051638B (zh) 2022-02-01
CL2015001914A1 (es) 2015-09-04
EP4410380A3 (en) 2024-10-23
IL239722A0 (en) 2015-08-31
SG11201505240QA (en) 2015-08-28
EA039530B1 (ru) 2022-02-08

Similar Documents

Publication Publication Date Title
MX376822B (es) Composicion de liberacion demorada que comprende biguanida.
HK1255102A1 (zh) 杂环化合物及其应用
BR112016000299B8 (pt) composições, uso de uma composição, método para o combate dos fungos fitopatogênicos e uso dos componentes
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
NZ716840A (en) Combination formulation of two antiviral compounds
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
PH12015501096A1 (en) Composition for immediate and extended release
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
BR112018006314A2 (pt) composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX2018001517A (es) Derivados sustituidos de guanidina.
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
JOP20200030A1 (ar) مركب خماسي الحلقة
NZ728102A (en) Parasiticidal compositions comprising indole derivatives, methods and uses thereof
EP3181137A4 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
WO2016020408A3 (en) Compounds for preventing ototoxicity
IN2013MU03308A (OSRAM)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ANJI PHARMA (US) LLC

FG Grant or registration